Acadia Expected To Report Upbeat Results
Investors expect Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) to report upbeat results from a Phase III clinical trial of its Parkinson's disease psychosis treatment at the end of the month. Shares of the biopharmaceutical climbed 35 cents to close at $2.26.
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here